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National guidelines for the management of HIV-infected
children in South Africa have been developed as a consensus
document by practising HIV clinicians around the country.
Guidelines for antiretroviral (ARV) management of children
appear in a booklet distributed by the National Department of
Health (DoH) since mid-2004 (National Antiretroviral
Treatment Programme Guideline for Carers, National
Department of Health, South Africa, 2004). A comprehensive
booklet on management of HIV-infected children has also
been produced for the DoH which includes recommendations
on management with antiretroviral (ARV) therapy.
The South African national paediatric guidelines are based on
the recommendations provided by the World Health
Organization (WHO) (Scaling up antiretroviral therapy in
resource limited settings; treatment guidelines for a public
health approach WHO 2003). It is important to note that WHO
are updating their recommendations. Based on this some
amendments, e.g. the staging system, have already been
incorporated into the final version of the South African
national guidelines. Other recommendations are more recent
and have yet to undergo broader review. These have therefore
not formed part of the printed version of the South African
guidelines. It is anticipated that a process of updating the
guidelines needs to be put in place urgently. The national
guidelines are available on the government website
(www.health.gov.za), and clinicians are advised to update
themselves regularly at this website for any amendments that
may be made to the guidelines.
It is essential that clinicians involved with management of HIV-
infected children in both the private and the public sector are
familiar with national recommendations for treatment. The
majority of HIV-infected children will access care in the public
sector and many move between private and public sector.
Treatment choices made by private clinicians should take into
account what is available in the public service, particularly if
the patient is likely to access care from both sectors.
Owing to the scale of the HIV epidemic, and in order to reach
all those who need care, people need to have access to
comprehensive HIV care at health care facilities as close as
possible to their homes. Uncomplicated cases, both adult and
paediatric, should be managed at primary care facilities. The
South African national guidelines are designed for clinicians
practising at all levels of care. In many cases primary health
care nurses may need to commence and manage children and
adults on ARVs. Since ARV treatment is uncomplicated in most
cases, this should be well within the scope of practice of
appropriately clinically trained nurses.
GOALS OF ANTIRETROVIRAL THERAPY
The goals of ARV therapy for children are to increase
survival, improve quality of life and decrease HIV-related
morbidity and mortality.
■ The child's CD4 count should rise and remain above the
baseline count.
■ The child's viral load should become undetectable (< 400
copies/ml) and remain undetectable on ARV therapy,
although in some children a suppressed though detectable
viral load, with sustained elevation in CD4 count and
absence of intercurrent and/or opportunistic infection,
may be the best achievable goal.
ELIGIBILITY FOR ANTIRETROVIRAL THERAPY
Patients must satisfy clinical and social criteria before being 
accepted for treatment.
CLINICAL CRITERIA 
1. Confirmation of diagnosis of HIV infection. 
2. Recurrent (> 2 admissions per year) hospitalisations for
HIV complications or prolonged hospitalisation for HIV 
(> 4 weeks), or
3. The patient satisfies the provisional WHO citeria for stage
III/IV disease (see Interim Revised WHO Staging of Disease)
or
4. For relatively asymptomatic patients, one can consider
starting ARV if the CD4 percentage is < 20% (age under 18
months) or < 15% (age over 18 months). 
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SOCIAL CRITERIA 
These criteria are extremely important for the success of
the programme and need to be adhered to. The principle is
that adherence to treatment must be at least probable. 
1. At least one identifiable caregiver who is able to supervise
the child for administering medication (orphans and
vulnerable children (OVC) should not be discriminated
against and all efforts should be made to ensure that their
psychosocial circumstances be addressed so that they too
can receive treatment).
2. Disclosure to another adult living in the same house is
encouraged (but not mandatory), so that there is someone
else who may assist with the child's ART.
3. NB: Treatment of mother/caregiver/other family mem-
bers
■ Always ask about the caregiver's health, and the health
of other members of the family.
■ Ensure that mothers and other family members access
medical care timeously, including ART if needed. 
■ Where possible, HIV-positive mothers and caregivers
requiring medical attention should be attended to at the
same time as their children in order to decrease the
number of clinic visits and associated costs and time away
from work.
WHAT TO START?
Antiretroviral drug choices for children are set out in Table I.
GENERAL COMMENTS
■ All infants under 6 months of age who require ARV
therapy should preferably be started on treatment under
specialist supervision.
■ Stavudine solution requires refrigeration. If no fridge is
available, stavudine capsules may be opened and dissolved,
and the required amount administered to the child. The rest
can be discarded. If the caregiver experiences difficulty
with stavudine capsules, zidovudine suspension may be
used instead.
■ Switch to tablets or capsules from syrups or solutions as
soon as possible. 
■ Lopinavir/ritonavir (Kaletra®) needs to be kept cool 
(< 25°C).
■ Didanosine (ddl) must be taken alone, on an empty
stomach, at least an hour before (or 2 hours after) a meal.
Tablets should be dissolved in at least 30 ml of water. It is
important to use 2 tablets of didanosine to obtain
sufficient antacid buffering, e.g. if the child needs 100 mg
prescribe 2 x 50 mg tablets.
■ Children may occasionally need to change from a drug in
the first-line regimen to one from the second-line
regimen, because of intolerance or a serious adverse
reaction. Swapping limits the patient's second-line
treatment options. The decision to swap must be made by
a doctor with ARV experience. Swapping of one drug
should only be done if there is full viral suppression,
failing which the whole regimen may need to be altered. If
intolerance develops to ritonavir or lopinavir/ritonavir
(Kaletra®), switch to nelfinavir. Abacavir may be used if
adverse events on other nucleoside reverse transcriptase
inhibitors (NRTIs) occur.
■ Drugs not listed in the first- and second-line regimens but
mentioned in the guidelines, e.g. ritonavir, nelfinivir,
saquinavir, abacavir and nevirapine, should be available at
all tertiary care centres.
■ DoH guidelines have incorporated a dosing table that has
been based on weight bands in order to facilitate ease of
prescribing paediatric formulations (Table II).
ADVERSE EVENTS
The adverse event profile of ARVs is similar in adults and
children. Most side-effects of treatment are minor if they
occur, but on occasion severe adverse events may require
urgent referral to centres with expertise and ARVs may need
to be stopped. Such events include severe hepatitis, Stevens-
Johnson syndrome, pancreatitis, lactic acidosis (presenting
with severe gastrointestinal symptoms, pain, vomiting and/or
decreased level of consciousness). Refer to 'Guidelines for
management of the HIV-infected child' (www.health.gov.za)
for more detailed information regarding adverse events.
Children on stavudine may, like adults, develop peripheral
neuropathy and/or lipodystrophy/lymphoatrophy. These may
be subtle or more difficult to diagnose in children.
Nevertheless, a high index of suspicion may result in more
adverse events being detected in children in general.
Switching from stavudine to abacavir may be helpful if the
child has viral suppression.
Remember that all adverse events should be notified to the
Medicines Control Council (MCC). A copy of the yellow form
that is required to be completed may be found in the full
guidelines and/or is obtainable from the MCC offices.
ADHERENCE
Adherence greater than 95% will ensure a good virological
response and prevent the emergence of viral resistance. Good
adherence can be achieved with regular education and
support. Adherence may be monitored using diary cards,
medication check and other measures. All efforts should be
made to encourage this level of adherence.
6 months up to 3 years > 3 years and > 10 kg
1st line Stavudine (d4T) Stavudine (d4T)
Lamivudine (3TC) Lamivudine (3TC)
Kaletra® Efavirenz
2nd line Zidovudine (AZT) Zidovudine (AZT)
Didanosine (ddI) Didanosine (ddI)
Nevirapine/efavirenz* Kaletra®
* Efavirenz if the child is over 3 years and nevirapine if < 3 years.





















TABLE II. PAEDIATRIC ARV AND TRIMETHOPRIM/SULFAMETHOXAZOLE DOSING CHART FOR USE IN RESOURCE-CONSTRAINED SETTINGS
Trimethoprim/
sulfamethoxazole
Stavudine Lamivudine Zidovodine Didanosine Nevirapine TMP/SMZ
Weight Abacavir (Zerit® (Epivir®, (Retrovir®), ZDV, (Videx®, (Virammune®, NVP) Efavirenz Lopinaviriritonavir Nelfinavir Indinavir Septran, Bactrim®,
(kg) (Ziagen®) d4T) 3TC) AZT DDI) and trimethoprim sulphamethoxazole (Stocrin®, Sustiva®, EFV) (Kaletra®) (Viracept®) (Crixivan®) various)
Induction Maintenance dose < 15 kg = 12 mg 4 mg / kg
dose: lop/kg once daily
4 mg / kg ≥ 15 kg = 10 mg (For prophylaxis
once daily lop/kg against oppor-
for first 14 < 8 yrs ≥ 8 yrs twice daily tunistic illnesses.
8 mg / kg 1 mg / kg 4 mg / kg 240 mg/ m2 120 mg / m2 days, then 7 mg / kg 4 mg / kg Dose as shown (Iop = Iopinavir; 60 mg / kg 500 mg/m2 Doses for treat-
twice daily twice daily twice daily twice daily twice daily give twice daily twice daily once daily r = ritonavir) twice daily every 8 hours ment of bacterial
maintenance and protozoal
dose infections are 
higher than
listed here)
Liquid Tablet Capsules Liquid Tablet Liquid Capsule Chewable Liquid Tablet Liquid  Tablet Liquid Tablet Liquid Capsules Liquid Capsules Single-
20 300 15, 20, 30 10 150 10 100 tablets 10 200 10 200 10 200 30 50, 80 mg 133.3/33.3 Tablet Capsule Liquid strength
mg / ml mg mg mg / ml mg mg / ml mg 25, 50, 100 mg mg / ml mg mg / ml mg mg / mg mg / ml 200 mg lopinavir/ mg 250 mg 200 mg 8 mg / ml (SS) tablet
ml ml9 lop/r 80 mg TMP/
400 mg SMZ
5 - 6.9 2 ml 2 ml 7 ml 2 ml 4 ml 2 tabs 1 cap 3 ml





10 - 11.9 4 ml 15 mg (or 4 ml 12 ml 1 cap 25 mg + 4 ml 8 ml 
1
2




20 mg) 25 mg
12 - 14.9 5 ml 15 mg (or 5 ml 14 ml 1 cap 50 mg + 5 ml 9 ml 
1
2
 tab 9 ml 200 mg 2 ml 3 tabs 1 cap 7 ml 1 SS tab
20 mg) 25 mg
15 - 16.9 6 ml 15 mg (or 6 ml 
1
2
 tab 15 ml 2 caps 50 mg + 6 ml 10 ml 
1
2
 tab 10 ml 200 mg + 2.5 ml 1 cap 3 tabs 2 caps 8 ml 1 SS tab
20 mg) 25 mg 50 mg
50 mg + 1 tab 200 mg +
17 - 19.9 7 ml 
1
2
 tab 20 mg 7 ml 
1
2






50 mg + 1 tab 200 mg +
20 - 24.9 9 ml 
1
2
 tab 20 mg 9 ml 
1
2
 tab 20 ml 2 caps 50 mg 9 ml 
1
2
 tab 16 ml a.m. + 9 ml 
1
2










27.9 ml 3 caps or
kg 300 mg 100 mg + 200 mg +
25 - 29.9 28 - 12 30 mg 11 ml 1 tab 24 ml tab 25 mg 11 ml 
1
2
 tab 20 ml 1 tab 11 ml 
1
2
 tab 15 ml 3 x 50 mg              3.5 ml 2 caps 5 tabs 2 caps 14  ml 2 SS tabs
29.9 ml 1 tab
kg
3 caps or 100 mg + 1 tab 30- 200 mg +
30 - 34.9 13 ml 1 tab 30 mg 13 ml 1 tab 27 ml 300 mg 25 mg 13 ml 1 tab 13 ml a.m.+ 32.9 15 3 x
tab 1
2
 tab kg ml 50 mg 4 ml 3 caps 5 tabs 3 caps 17 ml 2 SS tabs
p.m. 33- 17 200 mg +
34.9 ml 200 mg
kg
3 caps or 100 mg + 1 tab a.m. 200 mg +
35 - 40 15 ml 1 tab 30 mg 15 ml 1 tab 30 ml 300 mg 25 mg 15 ml 1 tab 15 ml + 
1
2
 tab p.m. 17 ml 200 mg 5 ml 3 caps 5 tabs 3 caps 20 ml 2 SS tabs
tab
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It is not possible for health care providers to reliably predict
which caregivers or individuals will ultimately be adherent to
their treatment plan, as adherence does not correlate with
gender, cultural background, socioeconomic or education
level, or language barriers between provider and patient. It is
therefore essential to provide all caregivers with a
comprehensive plan to support adherence. Several strategies
need to be applied and all members of the health care team,
as well as family and possibly even community-based support
groups, need to be involved.
Experience has shown that adherence decreases as time
progresses. Monitoring and support of adherence is therefore
essential. Some factors affecting adherence to paediatric ART
are listed below. A trusting relationship between the patient
and caregiver and members of the health care team is
essential. Optimal adherence requires full participation by the
health-care team. 
Every interaction with the patient and caregiver provides
an opportunity for reinforcing the absolute need for
adherence.
SOME IMPORTANT FACTORS DIMINISHING
ADHERENCE IN CHILDREN
■ Unanticipated drug side-effects and adverse events.
■ Intercurrent illness.
■ Caregiver illness/death or otherwise occupied.
■ Patient resistance to taking medicines – ritonavir, singly or
in combination with lopinavir, has a very bitter taste.
■ Change or absence of patient's nurse or doctor.
■ Frequent daily doses – e.g. twice or three times per day.
NB: Every effort should be made to ensure that every child
who needs ARV can access this regardless of home
circumstances. If necessary involve counsellors, social workers
or even the school to ensure that the child may be adherent to
his/her ARV therapy. In even the worst social circumstances a
creative solution can and must be found.
SWITCHING TO SECOND-LINE THERAPY
Reasons for switching to second-line therapy are set out in
Table III.
N.B.: Changing from first- to second-line ARV is a
decision that is undertaken only after careful
consideration. It is not something that one would rush
into before considering possible improvements in
managing therapy at home.
First check adherence: if it is not possible to improve
adherence, attempt directly observed therapy (DOT) with a
health care worker or the trusted 'other' family member or
friend identified under 'social criteria' above.
It is essential that switching ARV regimens is done in
consultation with a paediatrician with ARV experience.
CONCOMITANT TUBERCULOSIS
Tuberculosis occurs commonly with HIV. There are two 
scenarios to consider:
1. Child presents with tuberculosis before commencing
ARV therapy.
■ Complete TB therapy if possible before commencing ARV
therapy or delay ART for at least 2 months (in severe cases
it may be necessary to commence ARVs even sooner).
■ If the child has failed the nevirapine vertical transmission
programme or is less than 3 years old or weighs < 10 kg,
use ritonavir as the third drug.
■ If the child was not on the nevirapine vertical transmission
programme and is more than 3 years old and weighs more
than 10 kg, use efavirenz as the third drug (monitor
alanine transaminase (ALT) monthly).
2. Child develops tuberculosis while on ARV therapy.
■ If the child is on lopinavir/ritonavir or nelfinavir, then
switch to ritonavir.
■ If the child is on nevirapine, and is less than 3 years old or
weighs less than 10 kg, switch to ritonavir.
■ If the child is on nevirapine and is more than 3 years old
and weighs more than 10 kg, switch to efavirenz.
■ If the child is unable to tolerate the large number of drugs,
Clinical Immunological Virological
Lack of growth or Confirmed return of Rebound of viral 
decline of growth in CD4 percentage load to baseline.
a child showing (repeated within 1 (A detectable 
initial response month) to baseline viral load may 
to treatment or below before be tolerated in 
starting therapy children, 
Loss of neuro- in the absence of providing that 
developmental mile- concurrent illness growth and 
stones or develop- to explain CD4 elevated CD4 
ment of HIV decline count are 
encephalopathy sustained.)
More than 50% decline 
New evidence of in CD4 percentage 
stage III/IV disease from peak (confirmed 
(not immune within 1 month) 
reconstitution in the absence of 
syndrome: see concurrent illness to 
below) explain CD4 decline
Recurrence of prior 
opportunistic
infections, e.g. oral 
candidiasis that is 
refractory to 
treatment
Note: 1. Short episodes or isolated events of lower respiratory tract
infection and gastroenteritis should not necessarily be regarded as
clinical failure. 
2. Presentation with tuberculosis or other opportunistic infections
may be a sign of immune reconstitution inflammatory syndrome
(IRIS). This will usually be associated with a CD4 count and/or
percentage which have improved over time. This is NOT an
indication to switch to second-line therapy.
TABLE III. REASONS TO MOVE TO SECOND-LINE ARV
THERAPY IN CHILDREN
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ARV therapy may have to be interrupted until TB therapy
has been completed (always discuss this with an
experienced paediatric HIV clinician).
■ Monitor ALT monthly.
Note: Discuss all cases with a paediatrician with ARV












Extensive human papillomavirus infection 
Extensive molluscum contagiosum 
Fungal nail infections 
Recurrent oral ulcerations 




Recurrent or chronic respiratory tract infections (otitis media,
otorrhoea, sinusitis)
Clinical stage 3
Moderate unexplained malnutrition not adequately responding
to standard therapy 
Unexplained persistent diarrhoea (14 days or more)
Unexplained persistent fever (intermittent or constant, for
longer than 1 month)
Oral candidiasis (outside neonatal period )
Oral hairy leukoplakia
Acute necrotising ulcerative gingivitis/periodontitis 
Pulmonary tuberculosis
Severe recurrent presumed bacterial pneumonia 
Unexplained anaemia (< 8 g/dl), and/or neutropenia 
(< 500/mm3) and/or thrombocytopenia (< 50 000/mm3) for
more than 1 month
Chronic HIV-associated lung disease including bronchiectasis
Symptomatic lymphoid interstitial pneumonitis (LIP)
Clinical stage 4
Unexplained severe wasting or severe malnutrition not
adequately responding to standard therapy
Pneumocystis pneumonia
Recurrent severe presumed bacterial infections (e.g. empyema,
pyomyositis, bone or joint infection, meningitis, but excluding
pneumonia)
Chronic herpes simplex infection (orolabial or cutaneous of




CNS toxoplasmosis (outside the neonatal period)
HIV encephalopathy
Cytomegalovirus infection (CMV retinitis or infection of organs
other than liver, spleen or lymph nodes; onset at age 1 month
or more) 
Extrapulmonary cryptococcosis including meningitis




Disseminated non-tuberculous mycobacterial infection 
Candida of trachea, bronchi or lungs
Visceral herpes simplex infection
Acquired HIV-associated rectal fistula 
Cerebral or B-cell non-Hodgkin’s lymphoma
Progressive multifocal leukoencephalopathy (PML)
HIV-associated cardiomyopathy or HIV-associated nephropathy
*For persons aged under 15 years with confirmed laboratory evidence
of HIV infection; HIV antibody if aged 18 months and above;
virological or p24 antigen testing if aged under 18 months.
TABLE V. INTERIM REVISED WHO CLINICAL STAGING OF
HIV/AIDS FOR INFANTS AND CHILDREN*
We would like to acknowledge all HIV clinicians around the country
who assisted with the development of the above guidelines.
Regimen Test Frequency
d4T/3TC/ CD4% and/or Staging, 6-monthly
lopinavir CD4 count
+ ritonavir VL Baseline, 6-monthly 
(Kaletra®) Random cholesterol Baseline, 6-monthly
Random glucose Baseline, 6-monthly
ALT and FBC Baseline, 6-monthly
d4T/3TC/EFV CD4% and/or Staging, 6-monthly
CD4 count
VL Baseline, 6-monthly
ALT and FBC Baseline 6-monthly
ddI/AZT/ CD4% and/or Staging, 6-monthly
nevirapine CD4 count
VL Baseline, 6-monthly 
FBC Baseline, then monthly 
for 3 months,
then 6-monthly (with 
CD4 and VL) 
thereafter
ALT Baseline, week 2, 4 and
8, thereafter 
6-monthly
ddI/AZT/EFV CD4% and/or CD4 count 6-monthly
FBC Baseline, then monthly 
for 3 months,




ddI/ABC/EFV CD4% and/or CD4 count 6-monthly
ALT 6-monthly
FBC 6-monthly (with VL 
and CD4 + count)
*If the random cholesterol is elevated, perform fasting cholesterol and fasting
triglycerides.
Staging = initial testing (screening) for all patients when being referred for
antiretroviral therapy; Baseline = testing for ART eligible patients, at initiation of
ART;  VL = viral load; ALT = alanine transaminase; FBC = full blood count.
It is at the discretion of the initiator of ART to decide whether monitoring for
efficacy or toxicity be done outside of the routine schedule.
N.B.: For all regimens a baseline serum lipase is useful. This may be repeated if
there is clinical indication to do so. 
TABLE IV. PAEDIATRIC ARV REGIMENS AND ROUTINE
MONITORING DURING TREATMENT
